Fig. 7

Small molecules to CRISPR-identified targets inhibit SARS-CoV-2 infection. A The log₂FC across the studies performed in this work for the 12 gene targets that had commercially available inhibitors. The + and – signs to the right of the heat map summarize the ability of these small molecules to prevent SARS-CoV-2 infection of Vero E6 cells. B Initial screening of drug inhibition of SARS-CoV-2-induced cytotoxicity in Vero E6 cells following MOI 0.3 infection. Error bars are the mean and standard deviation of 6 biological replicates from two technical replicates. C Drug inhibition of SARS-CoV-2 genome replication was measured by RT-qPCR at 2 dpi of Vero E6 cells at MOI 0.01. One-way ANOVA was used to compare inhibitor-treated toxicity values to virus-alone controls. Error bars are the mean and standard deviation of 3 biological replicates. D–J The EC₅₀ (ability of inhibitors to reduce SARS-CoV-2 cytotoxicity) and CC₅₀ (toxicity of inhibitors alone) curves were obtained by cytotoxicity assays in Vero E6 cells. The selectivity indices are also shown. Non-linear regression of the data points was used to determine the EC₅₀ and CC₅₀ values. Error bars indicate standard deviation for all panels (n = 3 biological replicates)